Ivabradine Tablet, Film Coated
Product Images NDC 72603-934

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ivabradine (NDC 72603-934). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ivabradine-5mg-60s-cntr (Ivabradine 5mg 60s Cntr)

Ivabradine Tablets 5 mg film-coated tablets label. The package contains 60 film-coated tablets. The label notes the product is manufactured for Northstar Rx LLC and by MSN Laboratories Private Limited, Telangana, India. Storage instructions and barcode are also visible.*

FDA Label Image

Ivabradine-7-5mg-60s-cntr (Ivabradine 7 5mg 60s Cntr)

Label for Ivabradine Tablets 7.5 mg film-coated tablets by Northstar Rx LLC. The label states it contains 60 tablets, with detailed storage instructions and manufacturer info: MSN Laboratories Private Limited, India. Includes barcode and pharmacy dispensing note for the medication guide.*

FDA Label Image

Ivabradine-figure-1 (Ivabradine Figure 1)

Chemical structure of Ivabradine, depicting its molecular arrangement including methoxy groups, nitrogen atoms, and a lactam ring as part of the structure associated with this active ingredient.*

FDA Label Image

Ivabradine-figure-2 (Ivabradine Figure 2)

A forest plot illustrating the fold change and 90% confidence intervals for pharmacokinetic measures (Cmax and AUC) of ivabradine when coadministered with various CYP3A4 inhibitors, inducers, and other drugs. The chart includes recommendations such as contraindication, avoidance, or no dose adjustment based on the interaction magnitude relative to ivabradine alone.*

FDA Label Image

Ivabradine-figure-3 (Ivabradine Figure 3)

A line graph comparing the proportion of patients experiencing heart failure hospitalization or cardiovascular death over time (up to 36 months) between those treated with Ivabradine and placebo. The x-axis represents time from randomization in months, and the y-axis shows the proportion percentage. The graph also includes the number of subjects at risk for each time interval for both treatment groups.*

FDA Label Image

Ivabradine-figure-4 (Ivabradine Figure 4)

A forest plot comparing the hazard ratios (HR) and 95% confidence intervals (CI) for Ivabradine versus placebo across various subgroups including age, age quartile, sex, race, cause of heart failure, weight quartile, baseline heart rate quartile, NYHA class, baseline left ventricular ejection fraction quartile, baseline beta blocker use quartile, baseline aldosterone antagonist use, diabetes history, and hypertension history. The plot visually displays population percentages, event counts, and HR estimates for each subgroup, illustrating the comparative effects of Ivabradine relative to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.